Not exact matches
Now, a new study led by
infectious disease researcher Dr. Sachiko Seo, formerly of Fred Hutch and now a physician at the National
Cancer Research Center East in Chiba, Japan, and Boeckh and published last month in the journal Haematologica has found that like more «serious» viruses, rhinovirus can cause pneumonia — and when it does, it can be deadly to those recovering from transplantation.
The article was co-authored by leaders in HIV vaccinology, including Anthony S. Fauci, M.D., director of the National Institute of Allergy and
Infectious Diseases, part of the National Institutes of Health, and lead author Lawrence Corey, M.D., of the Fred Hutchinson
Cancer Research Center.
The new work, by
infectious diseases researcher Lawrence Corey and his colleagues at the University of Washington and the Fred Hutchison
Cancer Research Center, both in Seattle, goes even further.
«
Research in the last couple of decades has shown that microbes can exploit [cell death] pathways to cause disease,» says study coauthor Tobias Hohl, an
infectious disease researcher at Memorial Sloan Kettering
Cancer Center in New York City.
PHILADELPHIA --(July 11, 2017)-- Researchers at The Wistar Institute, an international leader in biomedical
research in the fields of
cancer, immunology and infectious diseases, with collaborators at Indiana University Melvin and Bren Simon Cancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (M
cancer, immunology and
infectious diseases, with collaborators at Indiana University Melvin and Bren Simon
Cancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (M
Cancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).
Key institutions in this collaborative team included the Broad Institute, Harvard University, CDC, NIAID, Tulane University, University of Edinburgh, Kenema Government Hospital, Scripps
Research Institute, Massachusetts Institute of Technology (MIT), the US Army Medical
Research Institute of
Infectious Diseases (USAMRIID), DNAnexus, Médecins Sans Frontières (MSF), Université Chiekh Anta Diop, Redeemers University Nigeria, University of Sierra Leone, the Sierra Leone Ministry of Health and Sanitation, University of Sydney, and the Fred Hutchinson
Cancer Research Center.
The 19 NIH institutes,
centers and offices contributing to the Knockout Mouse Project are: the NIH Office of Strategic Coordination / Common Fund; NCRR; the National Eye Institute; NHGRI; the National Institute of Allergy and
Infectious Diseases; the National Heart, Lung and Blood Institute; the National Institute on Aging; the National Institute of Alcohol Abuse and Alcoholism; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; NIDCD; the National Institute of Dental and Craniofacial
Research; the National Institute of Environmental Health Sciences; the National Institute of General Medical Sciences; the National Institute of Mental Health; the National Institute of Neurological Disorders and Stroke; the National Institute of Diabetes and Digestive and Kidney Diseases; the National
Cancer Institute; and the Office of AIDS
Research.
Funding: NIH's National Institute of Allergy and
Infectious Diseases (NIAID), National
Cancer Institute (NCI), and National
Center for
Research Resources (NCRR); the Bill and Melinda Gates Foundation; and the International AIDS Vaccine Initiative and its donors, including the U.S. Agency for International Development (USAID).